Shanghai RAAS Blood Products Co., Ltd.
002252.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$33.36B
Close$
$3.47
29.4% downside
Current Fair Value
29.4% downsideOvervalued by 29.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $33.36 Billion |
|---|---|
| Enterprise Value | $35.48 Billion |
| Dividend Yield | $0.05 (0.95%) |
| Earnings per Share | $0.24 |
| Beta | 0.33 |
| Outstanding Shares | 6,588,966,885 |
Return
| Return on Equity | 3.73% |
|---|---|
| Return on Assets | 3.22% |
| Return on Invested Capital | 3.31% |
Valuation & Multiples
| P/E Ratio | 27.59 |
|---|---|
| PEG | -108.06 |
| Price to Sales | 4.91 |
| Price to Book Ratio | 1.23 |
| Enterprise Value to Revenue | 5.37 |
| Enterprise Value to EBIT | 30.5 |
| Enterprise Value to Net Income | 29 |
| Total Debt to Enterprise | 0.1 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 24, 2026
EPS Estimate
$0.09
Average shareholder expectationRevenue Estimate
$2.33 B
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
$0.10
Average shareholder expectationRevenue Estimate
$1.70 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Shanghai RAAS Blood Products Co., Ltd.
4,045 employees
CEO: Jun Xu Shanghai RAAS Blood Products Co., Ltd. engages in the research, development, production, and sale of blood products. It provides human albumin, intravenous injection of human immunoglobulin, coagulation factor products, vaccines, diagnos...